MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • 2022 International Congress

    DNMT1 level and global DNA methylation in CD45+ blood cells in Parkinson’s disease

    A. Lavrinova, A. Zhuravlev, I. Miliukhina, E. Belykh, A. Tyurin, O. Berkovich, S. Pchelina, A. Emelyanov (Gatchina, Russian Federation)

    Objective: The aim of our study was to assess the alterations in DNA methyltransferase1 (DNMT1) level and global DNA methylation (5-mC) in CD45+ blood cells…
  • 2022 International Congress

    The study of clonidine growth hormone study amongst definite MSA, PD, PSP, and PAF patients to assess its feasibility as a future non-invasive biomarker

    S. Bhattacharjee, E. Vichayanrat, L. Watson, V. Iodice (London, United Kingdom)

    Objective: To analyze the sensitivity and specificity of the clonidine growth hormone (CGH) to distinguish probable multiple system atrophy (MSA) from pure autonomic failure (PAF),…
  • 2022 International Congress

    Clinical presentation of SNCA Duplication Parkinsonism in a Family Kindred

    K. Dent, M. Rochman, D. Kremens, J. Ratliff (Philadelphia, USA)

    Objective: To report phenotype variability in a family with SNCA duplication associated Parkinsonism. Background: Pathogenic variants in SNCA, the gene coding for α-synuclein, cause familial…
  • 2022 International Congress

    Myelination relevant plasma microRNA biomarkers identified via an innovative data analytic scheme for differential diagnosis of MSA, an Oligodendroglial Synucleinopathy

    CC. Lu, MC. Kuo, JW. Huang, Y-T. Tsai, H-H. Lin Wang, PJ. Kung, C-C. Wu, Y-Y. Hsueh, T. Ochiya, FKH. Phoa, S-P. Lin, R-M. Wu (Taipei, Taiwan)

    Objective: To establish an inclusive data analytic scheme to identify and characterize plasma microRNA biomarkers with pathophysiological significance for differentiating the atypical Parkinsonian, Multiple System…
  • 2022 International Congress

    IkT-148009 as a potential disease-modifying therapy in PD

    M. Werner, S. Karuppagounder, R. Rush, T. Kelly, T. Dawson, V. Dawson (Atlanta, USA)

    Objective: Modeling Parkinson’s disease in mice suggests c-Abl activation is required for PD initiation and progression, and therefore inhibition of c-Abl could be a strategy…
  • 2022 International Congress

    in vivo and autopsy validation of alpha-synuclein seeding activity using RT-QuIC assay in the gastrointestinal tract of patients with Parkinson’s disease

    C. Shin, JY. Han, YP. Choi, SI. Kim, SH. Park, HK. Yang, HJ. Lee, SH. Kong, YS. Suh, HJ. Kim, B. Jeon (Sejong-si, Republic of Korea)

    Objective: To evaluate pathologic alpha-synuclein (AS) seeding activity with Real-time quaking-induced conversion (RT-QuIC) assay using formalin fixed paraffine-embedded (FFPE) tissue of GI tract in Parkinson's disease (PD)…
  • 2022 International Congress

    Effect of CDNF in a novel combination stressor model of Parkinson’s disease

    A. Singh, A. Panhelainen, M. Voutilainen (Helsinki, Finland)

    Objective: In this study, our first aim was to develop a model for Parkinson's disease (PD) that would exhibit the alpha-synuclein (αSyn) aggregation pathology and…
  • 2022 International Congress

    Blaming neuromelanin for Parkinson’s disease: time-dependent tyrosinase overexpression drives endogenous synucleinopathy in non-human primates

    J. Lanciego, J. Chocarro, A. Fajardo-Serrano, A. Vazquez, AI. Rodriguez-Perez, J. Labandeira-Garcia, M. Vila, A. Rico (Pamplona, Spain)

    Objective: Development and characterization of a novel non-human primate model of Parkinson’s disease based on the AAV-mediated forced expression of human tyrosinase Background: Although neuromelanin…
  • 2022 International Congress

    Dopamine neuron platform for screening molecular mechanisms and inhibitory drugs against alpha-synuclein aggregation

    S. Er, I. Hlushchuk, P. Chmielarz, A. Domanskyi, M. Airavaara (Helsinki, Finland)

    Objective: Optimization of a dopamine neuron based,in vitro platform is beneficial for studying molecular mechanisms of alpha-synuclein aggregation,and screening of inhibitory drugs and deducing their…
  • 2022 International Congress

    α-Synuclein molecular behavior and proteomic profiling distinguish subtypes of Lewy body disorders

    I. Martinez-Valbuena, E. Swinkin, E. Santamaria Martinez, J. Fernandez-Irigoyen, V. Sackmann, A. Kim, P. Gonzalez-Latapi, G. Kuhlman, S. Bhowmick, NP. Visanji, AE. Lang, GG. Kovacs (Toronto, Canada)

    Objective: We hypothesized that the clinical heterogeneity found in Lewy body disorders is a consequence of the molecular diversity of αSyn between different patients as…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 51
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Kratom withdrawal induced orobuccal dyskinesia
  • Welcome to the MDS Abstracts Site
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley